Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|September 2, 2005
- Pharmaceutical Technology-09-02-2005
- Volume 29
- Issue 9
Analytical Method Equivalency: An Acceptable Analytical Practice
Participants in a 2003 PhRMA workshop present the industry’s current thinking on developing analytical method equivalency, including the importance of sample selection, acceptance criteria, data evaluation, and documentation.
Advertisement
Articles in this issue
about 21 years ago
Securing the Supply Chain With RFIDabout 21 years ago
Applications of Poly(ethylene in Drug Delivery Systems: Part IIabout 21 years ago
September 2005about 21 years ago
Pilots and Partnerships Move RFID Forwardabout 21 years ago
Reshaping CMC Development Servicesabout 21 years ago
Wash. Rinse. Repeatabout 21 years ago
Outsourcing Atrophy: A Cautionary Taleabout 21 years ago
In the Spotlight-September 2005Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement